Cancer Clinical Trial - Samumed SM08502-ONC-01
CONDITION(S): Advanced Solid Tumors - TRIAL: Samumed SM08502-ONC-01 - A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
This study is an open-label, multi-center, dose-escalation study in adult subjects with advanced solid tumors for whom standard therapy is not available for their stage of disease. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics (preliminary anti-tumor activity and gene expression analysis) of SM08502 administered orally, once daily, for 28 consecutive days. Dosing in 28-day cycles will continue within each subject, unless treatment is discontinued due to toxicity, disease progression, initiation of a new anti-neoplastic therapy, withdrawal of consent, the Sponsor terminates the study, or the subject no longer meets retreatment criteria.